SCHEMBL30520652

SCHEMBL30520652

CN1CCC(Nc2c(Cl)cnc3[nH]c(-c4ccc(N5CCN(C)CC5)cc4)nc23)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 4/20 0.55
JAK1 P23458 4/20 0.55
JAK3 P52333 2/20 0.55
ALK Q9UM73 4/20 0.48
INSR P06213 2/20 0.48
TNKS O95271 2/20 0.41
PARP1 P09874 2/20 0.41
TNKS2 Q9H2K2 2/20 0.41
AURKA O14965 1/20 0.41
KCNH2 Q12809 1/20 0.41
FGFR1 P11362 1/20 0.40
FGFR2 P21802 1/20 0.40
FGFR4 P22455 1/20 0.40
FGFR3 P22607 1/20 0.40
SYK P43405 1/20 0.39
IKBKB O14920 1/20 0.39
CHEK1 O14757 1/20 0.39
HRH4 Q9H3N8 1/20 0.39
DGAT1 O75907 1/20 0.39
PIM1 P11309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19778609 1.00 JAK2 (0.55) JAK2JAK1JAK3ALKINSR
SCHEMBL30520973 0.97 JAK2 (0.53) JAK2JAK1JAK3ALKINSR
SCHEMBL19778622 0.97 JAK2 (0.53) JAK2JAK1JAK3ALKINSR
SCHEMBL30521110 0.94 JAK2 (0.52) JAK2JAK1JAK3ALKINSR
SCHEMBL19779000 0.94 JAK2 (0.52) JAK2JAK1JAK3ALKINSR
SCHEMBL30520721 0.93 JAK2 (0.53) JAK2JAK1JAK3ALKINSR
SCHEMBL19778624 0.93 JAK2 (0.53) JAK2JAK1JAK3ALKINSR
SCHEMBL23937992 0.93 JAK1 (0.49) JAK2JAK1JAK3ALKINSR
SCHEMBL30521386 0.93 JAK2 (0.51) JAK2JAK1JAK3ALKINSR
SCHEMBL23937990 0.93 JAK2 (0.51) JAK2JAK1JAK3ALKINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11660303-B2 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity KANCERA AB (SE) 2023-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11660303-B2 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity ROR1, RORB, RORA JAK2 28/4885JAK1 8/4885JAK3 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.